Stocks›Healthcare›JAZZ

JAZZ

Jazz Pharmaceuticals plc

NasdaqResearch view

$237.95+0.71%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 5, 2025 and Nov 6, 2024, after the close.

Last report

Aug 3, 2026+3.99%

after the close

Last 4, next close

median 5.83% either way

up 4 of 4

Every report since 2023 →

DateEventSourceNext close

Aug 25U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaGlobeNewswireGlobeNewswire+2.26%
Aug 3Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗+3.99%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

21 big days: a close more than 2.98% from the one before, three times JAZZ’s median day (0.99%). On 4 of 21, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

21Aug 26, 2026
Aug 26, 2026Nothing in our recordNo JAZZ story, brief or results filing in our record that dayGroup −1.6% did not move with it
−1.6% did not move with itLLY −3.6 · MRK −2.1 · JNJ −1.1 · ABBV −1.1
−4.20%
20Aug 11, 2026
Aug 11, 2026Nothing in our recordNo JAZZ story, brief or results filing in our record that dayGroup −0.6% did not move with it
−0.6% did not move with itLLY −1.4 · ABBV +0.8 · JNJ −0.8 · MRK −0.4
−3.33%
19Aug 4, 2026
Aug 4, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.2% did not move with it
−0.2% did not move with itABBV −0.5 · LLY −0.5 · JNJ +0.2 · MRK +0.2
+3.99%
18Jul 21, 2026
Jul 21, 2026Nothing in our recordNo JAZZ story, brief or results filing in our record that dayGroup +1.3% did not move with it
+1.3% did not move with itLLY +2.5 · MRK +1.5 · ABBV +1.1 · JNJ +0.7
+4.42%
17Jun 29, 2026
Jun 29, 2026Nothing in our recordNo JAZZ story, brief or results filing in our record that dayGroup +1.0% did not move with it
+1.0% did not move with itLLY +1.8 · JNJ +1.5 · MRK +0.6 · ABBV +0.4
+3.35%
16Jun 4, 2026
Jun 4, 2026Before our storiesGroup +4.0% moved the same way
+4.0% moved the same wayMRK +4.8 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
+3.95%
15May 19, 2026
May 19, 2026Before our storiesGroup +1.8% moved the same way
+1.8% moved the same wayLLY +3.4 · ABBV +2.1 · MRK +1.5 · JNJ +0.5
+3.44%
14May 6, 2026
May 6, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.3% did not move with it
−0.3% did not move with itABBV −0.5 · JNJ −0.4 · MRK +0.4 · LLY −0.2
+7.68%
13Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% moved the same way
+1.9% moved the same wayLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+3.22%
12Mar 27, 2026
Mar 27, 2026Before our storiesGroup −0.1% did not move with it
−0.1% did not move with itLLY −2.1 · ABBV −0.8 · MRK +0.6 · JNJ +0.5
−3.42%
11Feb 26, 2026
Feb 26, 2026Before our storiesGroup −0.8% did not move with it
−0.8% did not move with itMRK −2.6 · ABBV −1.0 · JNJ −0.7 · LLY −0.7
−3.99%
10Feb 25, 2026
Feb 25, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.9% did not move with it
−0.9% did not move with itLLY −1.3 · MRK −1.2 · ABBV −0.7 · JNJ −0.5
+13.23%
9Jan 14, 2026
Jan 14, 2026Before our storiesGroup +1.4% did not move with it
+1.4% did not move with itMRK +2.5 · JNJ +2.3 · ABBV +0.5 · LLY −0.4
+5.16%
8Jan 8, 2026
Jan 8, 2026Before our storiesGroup −1.4% did not move with it
−1.4% did not move with itABBV −4.0 · MRK +2.2 · LLY −2.1 · JNJ −0.8
−5.38%
7Jan 6, 2026
Jan 6, 2026Before our storiesGroup +1.5% did not move with it
+1.5% did not move with itLLY +2.2 · ABBV +1.7 · MRK +1.3 · JNJ +0.2
−4.24%
6Dec 9, 2025
Dec 9, 2025Before our storiesGroup −1.2% did not move with it
−1.2% did not move with itMRK −2.1 · LLY −1.5 · JNJ −0.8 · ABBV −0.1
−3.95%
5Dec 2, 2025
Dec 2, 2025Before our storiesGroup −0.6% did not move with it
−0.6% did not move with itLLY −1.1 · MRK −0.8 · ABBV −0.3 · JNJ +0.0
−3.14%
4Nov 18, 2025
Nov 18, 2025Before our storiesGroup +0.5% did not move with it
+0.5% did not move with itMRK +3.8 · LLY +0.8 · JNJ +0.2 · ABBV −0.1
+6.13%
3Nov 17, 2025
Nov 17, 2025Before our storiesGroup +0.3% did not move with it
+0.3% did not move with itJNJ +1.9 · ABBV +0.7 · LLY −0.3 · MRK −0.1
+20.57%
2Nov 13, 2025
Nov 13, 2025Before our storiesGroup +0.5% did not move with it
+0.5% did not move with itMRK +1.6 · LLY +0.5 · JNJ +0.4 · ABBV −0.4
+3.66%
1Oct 1, 2025
Oct 1, 2025Before our storiesGroup +6.5% moved the same way
+6.5% moved the same wayLLY +8.2 · MRK +7.4 · ABBV +5.5 · JNJ +0.3
+3.87%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in JAZZ’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$15.4B

Revenue$4.3B+4.90%

Net income$-356.1M

EPS, diluted$-5.84−167.50%

Operating margin-10.1%

Return on equity-8.2%

Debt / equity1.48

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$15.4B

Enterprise Value$20.4B

Income$-356.1M

Sales$4.3B

Book/sh$66.53

Cash/sh$21.44

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio1.67

Current Ratio1.86

Debt/Eq1.48

EPS (ttm)$-5.84

EPS this Y-167.5%

EPS past 3/5Y—

Sales past 3/5Y5.3%

EPS Y/Y TTM-167.5%

Sales Y/Y TTM4.9%

Shs Outstand64.91M

ROA-3.1%

ROE-8.2%

ROIC-2.6%

Gross Margin—

Oper. Margin-10.1%

Profit Margin-8.3%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$3.1B

FY21

$3.7B

FY22

$3.8B

FY23

$4.1B

FY24

$4.3B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$3.1B	$3.7B	$3.8B	$4.1B	$4.3B
Gross Profit	—	—	—	—	—
Operating Income	$170.3M	$-65.5M	$578.6M	$716.6M	$-430.2M
Net Income	$-329.7M	$-224.1M	$414.8M	$560.1M	$-356.1M
Diluted EPS	$-5.52	$-3.58	$6.10	$8.65	$-5.84
Operating Cash Flow	$778.5M	$1.3B	$1.1B	$1.4B	$1.4B
Free Cash Flow	$750.9M	$1.2B	$1.1B	$1.4B	$1.3B

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

JAZZ story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Aug 25

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

The FDA approved two first-line Ziihera regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, expanding Jazz Pharmaceuticals’ commercial opportunity through its partnership with Zymeworks. The approval adds a near-term product catalyst for Jazz, but the available financial data still show a business with a -8.3% net margin and $-5.84 diluted EPS.

Since story

-8.6%

2026-08-25 → 2026-09-25

GlobeNewswire · 34d ago

View both sides →

Follow the news. Track the move.